Presentation is loading. Please wait.

Presentation is loading. Please wait.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Published byRandolf Hood Modified over 5 years ago

Similar presentations

Presentation on theme: "Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary."— Presentation transcript:

1 Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy.
Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. On day 8 after injection of both primary and secondary B16-OVA tumor cells (2 × 105), primary tumors of the right hindlimb were irradiated with a single dose of 15 Gy. In the following weeks, TILs were isolated and analyzed for PD-1 expression (A) and CTL function (B) of CD11ahigh CD8+ T cells. Data show percentages of PD-1+ in total CD11ahigh CD8+ TILs of 3 to 5 mice per group. *, P < 0.05; **, P < 0.01, compared with that in mice without radiotherapy (A). Arrow indicates day of radiotherapy (day 8). The production of IFNγ was analyzed by intracellular staining for IFNγ after a brief restimulation with OVA peptide ex vivo for 5 hours. Numbers in parentheses show the percentages of IFNγ-producing cells per PD-1+ population. C, B7-H1 (PD-L1) expression by CD45− (tumor cells) and CD45+ (leukocytes) cells within both tumor sites. D, LAG-3 and Tim-3 expression by CD11ahigh or CD11alow CD8+ TILs within both tumor sites. Sean S. Park et al. Cancer Immunol Res 2015;3: ©2015 by American Association for Cancer Research

Download ppt "Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary."

Similar presentations

Fig. 4. Activation of type‐1‐dependent antitumor cellular immunity by repeated DC1/Th1 tumor‐vaccine cell therapy in tumor‐bearing mice. (A)

Fig. 4. Activation of type‐1‐dependent antitumor cellular immunity by repeated DC1/Th1 tumor‐vaccine cell therapy in tumor‐bearing mice. (A)
Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.
Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs
Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic.

Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic.
CpG oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection by Anke R. M. Kraft, Frank Krux, Simone Schimmer,

CpG oligodeoxynucleotides allow for effective adoptive T-cell therapy in chronic retroviral infection by Anke R. M. Kraft, Frank Krux, Simone Schimmer,
IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.
ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.

ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.
LV DNA, genome, and capsid are not required for DC activation and CD8+ T cell priming in vivo. LV DNA, genome, and capsid are not required for DC activation.

LV DNA, genome, and capsid are not required for DC activation and CD8+ T cell priming in vivo. LV DNA, genome, and capsid are not required for DC activation.
Anti–4-1BB/PD-1 combination enhanced antigen-specific T-cell response.

Anti–4-1BB/PD-1 combination enhanced antigen-specific T-cell response.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Vascular HR ligand expression depends on tumor anatomical location.

Vascular HR ligand expression depends on tumor anatomical location.
Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.
mpJX-594 effects on tumor burden and leukocyte influx.

mpJX-594 effects on tumor burden and leukocyte influx.
Serial vaccination with 32Dp210-derived whole cell vaccines in non-tumor-bearing mice stimulates robust antileukemic cytolytic activity. Serial vaccination.

Serial vaccination with 32Dp210-derived whole cell vaccines in non-tumor-bearing mice stimulates robust antileukemic cytolytic activity. Serial vaccination.
CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.
Ag 85A–specific immune responses.

Ag 85A–specific immune responses.
Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Similar presentations

Ads by Google